Today feels like a small milestone. I have posted on LinkedIn every single day for a month. It might be too early to celebrate, but it is worth acknowledging. According to some studies, more than half of the people who…
Over the next few weeks, I will do a deep dive into AI in pharmacovigilance. I will read the key papers in this field and share what I learn with my network. My goals are simple. Become more knowledgeable about…
That was the final question in The Minds of Modern AI, where Geoffrey Hinton, Yoshua Bengio, Yann LeCun, Fei-Fei Li, Bill Dally, and Jensen Huang shared their perspectives. Their answers showed not just different timelines, but different philosophies of intelligence…
IPulse monitors the latest discoveries in biomedical sciences by continuously parsing new literature and extracting structured knowledge from it. We started with ESMO 2025. Our system processed all the abstracts and automatically identified: • Treatments • Targets • Clinical trial…
One surprising outcome from evaluating our drug repurposing system is how far into the future it can generate meaningful hypotheses – years before the biomedical community recognizes them. Here are three examples from our cystic fibrosis (CF) work. 1. Tamoxifen…
They often showcase how well a method can “rediscover” drug–disease links that already appear in the literature. That may look convincing, but it misses the real challenge: finding drug candidates that nobody has talked about before. In a true repurposing…
I’ve decided to go much deeper into drug safety and pharmacovigilance. Over the past year, we discovered that our LLM-based NLP approach works surprisingly well for PV. That led us to develop the IPV tool, and the results convinced me…
When I joined the Department of Statistics at Florida State University in 2007, I thought I’d spend my whole career in academia. Over 15 years, I moved from assistant to full professor, taught, advised students, and ran a lab. My…
After my last post on SBIR/STTR lessons, several people reached out with appreciation or follow-up questions. Here are the questions I received from Hua Jin and my answers. Q: How can I get involved as a reviewer? Contact program directors…
Over the years, quite a few people have asked me about my experience applying for SBIR/STTR grants. Since I’ve learned many lessons through trial and error, and after winning 6 SBIR/STTR awards since my first NSF STTR grant in 2014,…
